We are live on ! Find out more
CM

CM Management Portfolio holdings

AUM $120M
1-Year Est. Return 37.12%
This Fund
S&P 500
This Quarter Est. Return
+25.59%
1 Year Est. Return
+37.12%
3 Year Est. Return
+141.34%
5 Year Est. Return
+139.46%
10 Year Est. Return
–
AUM
$124M
AUM Growth
+$30.2M
Cap. Flow
+$9.62M
Cap. Flow %
7.73%
Top 10 Hldgs %
42.82%
Holding
77
New
12
Increased
24
Reduced
16
Closed
5

Top Buys

1
RPRX icon
Royalty Pharma
RPRX
+$3.44M
2
INTT icon
inTEST
INTT
+$1.59M
3
PFE icon
Pfizer
PFE
+$1.51M
4
OGN icon
Organon & Co
OGN
+$1.5M
5
NWL icon
Newell Brands
NWL
+$1.33M

Top Sells

1
NHC icon
National Healthcare
NHC
+$3.45M
2
SWN
Southwestern Energy Company
SWN
+$2.1M
3
TALO icon
Talos Energy
TALO
+$1.9M
4
DRRX
DURECT Corp
DRRX
+$1.31M
5
FNF icon
Fidelity National Financial
FNF
+$1.09M

Sector Composition

1 Healthcare 44.16%
2 Financials 8.39%
3 Technology 8.19%
4 Industrials 7.86%
5 Materials 7.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTLE
51
DELISTED
Vital Energy
VTLE
$682K 0.55%
+15,000
New +$719K
RVNC
52
DELISTED
Revance Therapeutics, Inc.
RVNC
$659K 0.53%
+75,000
New +$614K
HRTX icon
53
Heron Therapeutics
HRTX
$92.8M
$553K 0.44%
325,000
-125,000
-28% -$138K
NKTR icon
54
Nektar Therapeutics
NKTR
$2.3B
$531K 0.43%
62,656
+9,323
+17% +$70.6K
SFE
55
DELISTED
Safeguard Scientifics, Inc.
SFE
$527K 0.42%
671,671
– –
SMSI icon
56
Smith Micro Software
SMSI
$14.5M
$496K 0.4%
15,000
+7,500
+100% +$278K
RNAC icon
57
Cartesian Therapeutics
RNAC
$248M
$483K 0.39%
23,333
– –
BCDA icon
58
BioCardia
BCDA
$12.8M
$465K 0.37%
46,667
+6,667
+17% +$54.1K
CTSO icon
59
Cytosorbents Corp
CTSO
$22.5M
$461K 0.37%
415,000
-35,000
-8% -$52K
FEMY icon
60
Femasys
FEMY
$9.06M
$439K 0.35%
22,500
+16,250
+260% +$399K
ELTX icon
61
Elicio Therapeutics
ELTX
$84.8M
$417K 0.34%
50,000
-15,000
-23% -$97.8K
ASRT
62
DELISTED
Assertio
ASRT
$369K 0.3%
23,000
+11,824
+106% +$292K
LTRN icon
63
Lantern Pharma
LTRN
$37.1M
$342K 0.28%
80,000
+5,000
+7% +$17.6K
CRIS icon
64
Curis
CRIS
$9.41M
$319K 0.26%
1,250
-125
-9% -$19.9K
KRON
65
DELISTED
Kronos Bio
KRON
$313K 0.25%
250,000
– –
CADE
66
DELISTED
Cadence Bank
CADE
$296K 0.24%
10,000
– –
GANX icon
67
Gain Therapeutics
GANX
$70.4M
$294K 0.24%
90,000
– –
EDSA icon
68
Edesa Biotech
EDSA
$64M
$283K 0.23%
62,000
+2,343
+4% +$8.88K
ELDN icon
69
Eledon Pharmaceuticals
ELDN
$303M
$252K 0.2%
140,000
-94,803
-40% -$132K
CMPX icon
70
Compass Therapeutics
CMPX
$378M
$195K 0.16%
+125,000
New +$216K
NEUE
71
DELISTED
NeueHealth
NEUE
$137K 0.11%
18,000
-7,715
-30% -$51.8K
PVLA
72
Palvella Therapeutics
PVLA
$2.24B
$137K 0.11%
9,375
+1,257
+15% +$23K
DRRX
73
DELISTED
DURECT Corp
DRRX
– –
-525,000
Closed -$1.31M
VTOL icon
74
Bristow Group
VTOL
$1.29B
– –
-35,000
Closed -$986K
WKC icon
75
World Kinect Corp
WKC
$1.89B
– –
-30,000
Closed -$673K
1 2
3
4

Similar funds

AA
Ahara Advisors Jersey City, New Jersey $120M AUM
CC
Commons Capital Needham, Massachusetts $120M AUM 31.45% 1-Year Est. Return
DG
Dala Group Hoffman Estates, Illinois $120M AUM
ACM
AIHC Capital Management Central $120M AUM
WAG
Windsor Advisory Group Columbus, Ohio $120M AUM 4.29% 1-Year Est. Return
YMRC
Yorktown Management & Research Company Forest, Virginia $120M AUM 52.72% 1-Year Est. Return
IW
Integrated Wealthcare Durham, North Carolina $120M AUM
BCWM
Ball & Co Wealth Management Franklin, Tennessee $120M AUM 21.28% 1-Year Est. Return

CM Management's Q4 2023 Portfolio in Review

As of Q4 2023, CM Management held 77 positions worth $124M, up 32% from $94.2M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

CM Management deployed $9.62M of net new capital in Q4 2023, opening 12 new positions and adding to 24 existing holdings. Its largest new stake was Royalty Pharma: 125,000 shares worth $3.51M.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, up from 38% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was National Healthcare, an estimated $3.45M trimmed.

  • CM Management's largest Q4 2023 buy was Royalty Pharma: 125,000 shares worth $3.51M.
  • CM Management added most to Organon & Co in Q4 2023, an estimated $1.5M increase.
  • CM Management's biggest Q4 2023 reduction was National Healthcare, cutting an estimated $3.45M.
  • CM Management fully exited Southwestern Energy Company in Q4 2023, selling an estimated $2.1M.
  • CM Management's ten largest holdings make up 43% of its $124M portfolio in Q4 2023.
  • CM Management opened 12 new positions and closed 5 in Q4 2023.
  • CM Management's portfolio value rose 32% quarter-over-quarter to $124M.

Based on CM Management's 13F filing for Q4 2023, filed 12 Feb 2024.